Analyst Price Target is $11.00
▲ +727.07% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adial Pharmaceuticals in the last 3 months. The average price target is $11.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 727.07% upside from the last price of $1.33.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Adial Pharmaceuticals.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Read More